Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0NAZIB
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
AZD0516
|
|||||
| Synonyms |
AZD0516
Click to Show/Hide
|
|||||
| Organization |
AstraZeneca (Top20 MNC) (Originator)
|
|||||
| Drug Status |
Phase 1/2
|
|||||
| Antibody Name |
Anti-STEAP2 mAb
|
Antibody Info | ||||
| Antigen Name |
Metalloreductase STEAP2 (STEAP2)
|
Antigen Info | ||||
| Payload Name |
Exatecan
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
A cleavable linker
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Prostate cancer |
1 Trials
|
ADC-specific functional property(2027 Update)
Bystander Killing Effect
| Bystander Killing Effect | Description | Reference |
|---|---|---|
| yes |
Exatecan-driven bystander cell killing from intracellular release of payload was demonstrated in co-culture systems involving STEAP2-positive and negative cell lines.
|
[1]
|
References